Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price40.50 USD
Fair value39.00
RatingAVOID
Our investment reviews on this name
2026-07-02Read Accumulation39.62+2.2% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Centessa Pharmaceuticals plc holds its Accumulation at $40.50. Elevated stress, defensive posture warranted, held for 38 days.
As held on the ledger · 2026-08-24
Phase
Accumulation
Quantitative state
Elevated stress, defensive posture warranted, held for 38 days
Price at the screen
$40.50
Valuation
N/A trailing · -22.75 forward price to earnings
Values screen
PASS
Beta
1.12
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
1.93%
Below 33%
Interest-bearing debt is just 1.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
4.51%
Below 33%
Cash held in interest-bearing accounts and securities is 4.5% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Centessa Pharmaceuticals clears all five screens. Its business is in a permissible area, its debt is near-nil, and almost none of its income is interest, so it passes.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID: it trades above our $39.00 fair value estimate.
Fair value range in USD, drawn from the 2026-08-24 screen. The gold marker is the market price at the same screen. The price runs 3.7% above the base estimate.
Third-party analyst targets: 4 covering, consensus Hold. The average target sits −4% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-24 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Biotech dreams priced above fair value rarely deliver
Picture a lab racing to turn one promising molecule into a medicine that actually reaches patients. The clock ticks, cash burns, and regulators demand proof. Centessa sits in exactly that spot, with its shares changing hands at $40.50 against our fair value of $39.00.
We pass because the numbers give no margin. Forward earnings sit at a negative 22.8 times, profit margins remain at zero, and return on equity runs at minus 57 percent. Four analysts call it a hold with a median target of $39, yet the market already prices the story as if success is assured.
That leaves real downside if trials slip or dilution follows. The ethical screen clears, yet the valuation and cash losses still fail our basic test for owning the business today. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CNTA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Accumulation$40.50+0.0%Entry 6
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 47% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (7 analysts) rates it none, with a mean price target of $45.
2026-08-25Accumulation$40.50+0.0%Entry 5
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 47% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (7 analysts) rates it none, with a mean price target of $45.
2026-07-25Accumulation$40.50+2.2%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.2% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 47% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (7 analysts) rates it none, with a mean price target of $45.
2026-07-18Accumulation$39.62+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 47% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (7 analysts) rates it none, with a mean price target of $45.
2026-07-03Accumulation$39.62+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Accumulation$39.62Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
